Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 17, 2019, the Board of Directors (the “Board”) of Heat Biologics, Inc. (the “Company”) amended and restated the Company’s bylaws (the “Bylaws”), effective immediately. The Bylaws include the following amendments:
Section 2.5 has been amended to provide for additional forms of notice, including electronic mail.
Section 2.10 has been amended to provide that all elections and questions of stockholders at stockholder meetings (other than the election of directors) shall, unless otherwise provided by law, the Company’s certificate of incorporation, the Bylaws, the rules or regulations of any stock exchange applicable to the Company, or any law or regulation applicable to the Company or its securities, in which case such different or minimum vote shall be the applicable vote on the matter, be decided by the affirmative vote of the holders of a majority of the votes cast (excluding abstentions and broker non-votes) on such matter. The prior provision required the affirmative vote of holders having a majority of the shares present in person or represented by proxy and entitled to vote thereon (abstentions would have the same effect as votes against).
Section 2.14 has been amended to add language to provide that the number of nominees a stockholder may nominate for election at the annual meeting or special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting or special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting.
Section 4.6 has been amended to provide that the directors entitled to cast a majority of the votes of the whole Board shall constitute a quorum for the transaction of business by the Board. The prior provision provided a majority of directors in office shall constitute a quorum for the transaction of business by the Board.
Sections 7.1 and 7.2 have been amended to, among other things, to update the indemnity provision in accordance with the General Corporation Law of the State of Delaware (the “DGCL”) and to limit mandatory indemnification and advancement of expenses to present and former officers and directors. The prior provision provided mandatory indemnification and advancement of expenses to employees or agents in addition to directors and officers.
Section 8.9 has been amended to add a sentence to the end thereof that such Section 8.9, which sets forth provisions relating to forum selection, will not apply to claims arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or other federal securities laws for which there is exclusive federal or concurrent federal and state jurisdiction.
The Bylaws also include certain technical, conforming, modernizing and clarifying changes. The foregoing description is qualified in its entirety by the Bylaws which are attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
HEAT BIOLOGICS, INC. Exhibit
EX-3.1 2 htbx_ex3z1.htm AMENDED AND RESTATED BYLAWS AMENDED AND RESTATED BYLAWS EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF HEAT BIOLOGICS,…
To view the full exhibit click here
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
